— Applications due by February 28; selected applicants will be notified on March 31 —
BOSTON, January 5, 2021 – The Institute for Clinical and Economic Review (ICER) is now accepting applications for the inaugural cycle of a new Health Technology Assessment (HTA) Fellowship. The ICER HTA Fellowship is a paid full-time one-year program for post-master’s and post-doctoral graduates that provides experiential training alongside a team of evidence synthesis researchers and health economists.
“The ICER HTA Fellows will receive mentorship from HTA researchers, an opportunity to collaborate with health care experts around the country, and hands-on training in advanced statistical modeling,” said Steven D. Pearson, MD, MSc, ICER’s President. “We’re hopeful that this immersive program will not only launch these individuals’ careers across industry and academic settings, but that it will also build a pipeline of future HTA leaders in the US.”
Upon completion of the program, Fellows will be able to apply evidence synthesis strategies and methodologies to the evaluation of prescription drugs, medical tests, and other health care and health care delivery innovations. Graduates of this program will go on to conduct research in an academic institution, think tank, managed care organization, pharmaceutical company, or healthcare facility.
Fellowship applicants should have a PhD, PharmD, or a Master’s degree in a relevant discipline such as public health, epidemiology, health policy, pharmacy, or health economics.
Applications for the ICER HTA Fellowship are due on February 28, 2021. ICER will select the Fellow by March 31, 2021, and the anticipated start date will be August 2, 2021. Applications should include a resume, a cover letter, and a letter of recommendation from a faculty member or supervisor. Additional information about qualifications, Fellowship activities, and application guidelines is available on ICER’s website.
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system. ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.